Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: Evaluation of etanercept in rheumatoid arthritis

Canadian Journal of Clinical Pharmacology

Volumn 12, Issue 3, 2005, Pages

  Farahani, Pendar ^a,b   Levine, Mitchell ^a,b   Gaebel, Kathryn ^a   Thabane, Lehana ^a,b  

^a CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Comparative study; Etanercept; Post marketing study; Rheumatoid Arthritis

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MIXTURE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 30744460391     PISSN: 1198581X     EISSN: 17106222     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kuhlmann J. Drug research: from the idea to the product. Int J Clin Pharmacol Ther. 997;35:541-52.
2. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci. 1992;81:605-10.
3. Weissinger J. Pharmacology and toxicology of novel drug delivery systems. Regulatory issues. Drug Saf. 1990;5:107-13.
4. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ. 2005;172:765-67.
5. Streiner DL. The 2 "Es" of research: Efficacy and effectiveness trials. Canadian Journal of Psychiatry-Revue Canadienne de Psychiatrie 2002;47:552-56.
6. Wells KB. Treatment research at the crossroads: The scientific interface of clinical trials and effectiveness research. American Journal of Psychiatry 1999;156:5-10.
7. Corrigan OP. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. Social Science & Medicine 2002;55:497-507.
8. Linden M. Controlled clinical trials and postmarketing experience. Psychopharmakotherapie 1997;4:26-31.
9. Linden M. Differences in adverse drug reactions in phase III and phase IV of the drug evaluation process. Psychopharmacol Bull. 1993;29:51-56.
10. Lawson DH. Postmarketing surveillance versus clinical trials: which benefits the patient? Cardiology 1994;85:18-23.
11. Linden M. Phase-IV research: specifics, objectives and methodology. Pharmacopsychiatry 1984;17:140-42.
12. Community-Based Evaluation of Etanercept in Rheumatoid Arthritis Patients. Farahani P, Levine M, Gaebel K, Wang E, Khalidi N. J Rheumatology (in press)
13. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al. Etanercept therapy in rheumatoid arthritis - A randomized, controlled trial. Annals of Internal Medicine 1999;130:478-486.
14. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine 1999;340:253-59.
15. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New England Journal of Medicine 2000;343:1586-93.
16. Ware J. SF-36 Health Survey. Manual and Interpretation Guide. The Health Institute, New England Medical Centre.Boston 1993.
17. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthr Rheum 1980;23:137-45.
18. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36:729-40.
19. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-35.
20. Escalante A. What do self-administered joint counts tell us about patients with rheumatoid arthritis? Arthritis Care Res. 1998;11:280-90.
21. Pincus T, Callahan LF, Brooks RH, Fuchs HA, Olsen NJ, Kaye JJ. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann.Intern.Med 1989;110:259-66.
22. Deyo RA, Inui TS, Leininger JD, Overman SS. Measuring functional outcomes in chronic disease: a comparison of traditional scales and a self-administered health status questionnaire in patients with rheumatoid arthritis. Med Care 1983;21:180-92.
23. Pincus T, Sokka T, Kavanaugh A. Quantitative documentation of benefit/risk of new therapies for rheumatoid arthritis: patient questionnaires as an optimal measure in standard care. Clin Exp.Rheumatol. 2004;22:S26-S33.